MYRIAD GENETICS (MYD DU) stock market data APIs
€2.4483
0.46(18.8%)
as of July 31, 2026
Try our APIs with
free plan!
MYRIAD GENETICS Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for MYD.DU.
Prev. Close
2.4483
Open
2.9089
High
2.9197
Low
2.4336
52 wk Range
2.429-7.2
Market Cap
1 751 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MYRIAD GENETICS data using free add-ons & libraries
Get MYRIAD GENETICS Fundamental Data
MYRIAD GENETICS Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-07-30
- EPS/Forecast: -0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MYRIAD GENETICS News
New
Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook Amid Prenatal Test Weakness
In late July 2026, Myriad Genetics reported second-quarter 2026 results showing sales of US$190.7 million and a reduced net loss of US$43.2 million, while also lowering full-year 2026 revenue guidance...
Why Myriad Genetics (MYGN) Shares Are Falling Today
Why Myriad Genetics (MYGN) Shares Are Falling Today What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 46.1% in the afternoon session after the company reported disa...
Myriad Genetics Inc (MYGN) (Q2 2026) Earnings Call Highlights: Revenue Declines 11% Amid Payer ...
This article first appeared on GuruFocus. Total Revenue: $190.7 million, down 11% year over year. Test Volume: Decreased 1% year over year. Average Revenue per Test: Decreased 9% year over year, incl...
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
Myriad Genetics (MYGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.05 per share a year ago. These figures ...
Get MYRIAD GENETICS fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
